Citations

Mayo Clinic

Clear

344 citation(s) found for "Dušek, Tina".

Abstract PD4-05: Partially functional (hypomorphic) missense variants in BRCA2 are reduced penetrance pathogenic variants
Huang, H., Hu, C., Na, J , Kucera, Matthew, Simmons, Timothy , Mundt, E., Young, C. C., Lyra, P. C., Tan, Y. Y., Nathanson, K. L., Pal, T., Karam, R., Pesaran, T., Yadav, S., Domchek, S. M., Monteiro, A. N., Hughes, E., Chen, W., Richardson, M. E., Couch, F. J., Huang, H., Mundt, Erin, Heidari, Z., Lyra, Paulo C. , Nathanson, Katherine L. , Karam, Rachid , Pesaran, Tina , Hughes, E., Boddicker, Nicholas , Couch, F.J.

Clinical Cancer Research | February 17, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PD4-05-PD4-05

10.1158/1557-3265.sabcs25-pd4-05 Get It

Abstract Background: BRCA2 variants with partially aberrant RNA splicing have been associated with a relatively lower breast cancer risk (reduced penetrance) relative to canonical pathogenic variants. However, the existence of partial loss of function (hypomorphic) missense variants, conferring reduced penetrance, is less certain. Identification and assessment of the clinical relevance of such reduced penetrance pathogenic variants (RPPVs) is needed to provide accurate risk estimates. Methods: Comprehensive functional characterization of hypomorphic missense variants (n=70) in the BRCA2 DNA-binding domain, initially identified through homology-directed DNA repair (HDR) assays, was conducted through multiple independent functional assays, including HDR, CRISPR/Cas9-based endogenous targeting, RAD51 foci formation assay, and Poly(ADP-ribose) polymerase (PARP) inhibitor response assay. Risk estimates were obtained using two large datasets from patients referred for hereditary cancer testing. A ClinGen/ACMG/AMP model was used for clinical classification. Results: The variants consistently demonstrated hypomorphic HDR activity and endogenous survival in HAP1 targeted cells, decreased RAD51 foci formation, and increased sensitivity to PARP inhibitors. These variants were associated with a moderate increase in breast cancer risk, as shown in two independent studies: one using multivariable logistic analysis adjusted for age, ancestry and family history (OR=2.41, 95%CI=1.51-3.85) and another comparing frequencies of variants in breast cancer cases to public reference controls adjusted for ancestry (OR=2.09, 95% CI=1.16-4.08). The mean age of breast cancer diagnosis for carriers of hypomorphic variants was 57 years, which was significantly older than the mean age of diagnosis of 51 years for carriers of protein truncating variants. Functional data were combined with other evidence sources in a ClinGen/ACMG/AMP model to classify 14 variants as “likely pathogenic”. Conclusions: We identified partially functional, hypomorphic missense variants associated with reduced penetrance for breast cancer. Cancer risk management guidelines for this new category of variants should be revisited given that the associated breast cancer risks warrant high risk screening but do not meet the threshold at which risk reducing mastectomy is offered. This study supports a shift in paradigm to considering variant-based risks on a continuum, with implications for risk-appropriate cancer risk management. Citation Format: H. Huang, C. Hu, J. Na, M. Kucera, T. Simmons, E. Mundt, C. C. Young, Z. Heidari, P. C. Lyra, Y. Y. Tan, K. L. Nathanson, T. Pal, R. Karam, T. Pesaran, S. Yadav, S. M. Domchek, A. N. Monteiro, E. Hughes, N. Boddicker, W. Chen, M. E. Richardson, F. J. Couch. Partially functional (hypomorphic) missense variants in BRCA2 are reduced penetrance pathogenic variants [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PD4-05.
Abstract GS2-05: Primary Results from the HR+/HER2- Cohort of TBCRC-053 (P-RAD): A Randomized Trial of No, Low, or High Dose Preoperative RADiation with Pembrolizumab and Chemotherapy in Node-Positive, HER2-Negative Breast Cancer
Gupta, G., Ho, A. Y., Gharibpoor, Faeze , Abdou, Y., Anampa, J. D., Blitzblau, R. C., Calhoun, B. C., Dent, S. F., Carey, L. A., Bellon, J. R., Warren, L. E., Lu, J., Hieken, T. J., Taghian, A. G., Bardia, A., Traina, T. A., Plitas, George , Gallagher, K., Daugherty, K., Thompson, A. M., Krop, I., Wolff, A., Mittendorf, E. A., Fox, J., Hwang, E., Khan, A. J., Loene, J. P., Mutter, R., Patil, S., Santa-Maria, C., Vincent, B. V., Wright, J. L., Spring, L., Gupta, Gaorav P , Blitzblau, R.C., Calhoun, B.C., Casey, Dana L. , Dent, Susan , Bellon, J.R., Warren, LE, Hieken, Tina J. , Bardia, Aditya , Gallagher, K.K., Thompson, A. M., Krop, Ian E. , Mittendorf, E. A., Garber, Haven R. , Mutter, Robert W. , Santa-Maria, C.A.

Clinical Cancer Research | February 17, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: GS2-05-GS2-05

10.1158/1557-3265.sabcs25-gs2-05 Get It

Abstract Introduction: Hormone receptor positive (HR+), HER2- breast cancer (BC) is the most common subtype of BC. Despite advances in chemotherapy and endocrine therapy optimization, local and systemic recurrences frequently occur, especially for patients with node-positive disease. Recent data suggest a subset of patients with this tumor phenotype may benefit from the addition of anti-Programmed Death-1(aPD1) to neoadjuvant chemotherapy. However, T-cell infiltration (TCI), a biomarker of response to aPD1 and chemotherapy, is typically low in this BC subtype. Preclinical models show that combining preoperative radiation therapy (preop RT) with immune checkpoint inhibitors can enhance TCI and anti-tumor immunity. We conducted the first randomized trial to test whether no-, low- or high-dose RT combined with aPD1 increases TCI and improves responses in non-irradiated, metastatic lymph nodes in HR+/HER2- BC (NCT04443348). Materials & Methods: Eligible patients had ER and/or PR≥10%, HER2 negative invasive BC with clipped and biopsy-proven positive axillary node(s), cT1c-T4c, cN1-3, and at least one of the following criteria: grade 3 or grade 1-2 with cN2-N3, Ki67 >20%, or high genomic assay score. Between 2022-2024, 51 patients from 10 centers were randomized to no (0Gy; control arm), low (9Gy) or high (24Gy) doses of preop RT to the primary tumor with concurrent pembrolizumab followed by a 2-week tumor biopsy. Stratification factors were T1c vs. T2-4 and N1 vs. N2-3. Patients subsequently received pembrolizumab with 12 weeks of paclitaxel, followed by 4 cycles of adriamycin-cyclophosphamide (q2wk or q3wk) with pembrolizumab (200 mg q3 wks or 400 mg q6 wks). Surgery and adjuvant therapy followed standard-of-care. Dual co-primary endpoints were 2wk tumor TCI and nodal pathologic complete response (ypN0) at time of definitive surgery. TCI was assessed by multiplex immunofluorescence (pan-cytokeratin, CD3, CD8), using a rank-based Immunoscore (range 0-1), compared to baseline reference biopsies via two-tailed Mann-Whitney test. ypN0 was evaluated non-comparatively. Secondary endpoints included pCR and Residual Cancer Burden (RCB) 0/1. Results: Among 51 patients enrolled, 49 were evaluable for TCI and 48 for the ypN0 endpoint. Median age was 49.5 years (range 23-78). The cohort had a high-risk clinical profile: 92% had cT2-4, 50% N2-3, and 62% grade 3 tumors. Median ER and PR positivity were 90% (20-100) and 68% (1-98), respectively. Multifocal or multicentric tumors were present in 32%. TCI was assessed at 2 weeks post-treatment. The proportion of tumors with TCI in the upper quartile increased with RT dose escalation: 31% (0Gy), 40% (9Gy), and 53% (24Gy). Median TCI scores at 2 weeks were 0.60 (0Gy), 0.56 (9Gy), and 0.82 (24Gy), compared to a median baseline value of 0.50 from untreated reference samples. A statistically significant increase in TCI was observed only in the 24Gy cohort relative to the untreated group (p=0.027). 70.8% underwent mastectomy, with 39.6% receiving immediate reconstruction. 8% experienced G2/3 wound complications, balanced across arms. Median number of lymph nodes removed was 6.5 (1-42). The overall ypN0 rate was 29%, and 24%(0Gy), 29%(9Gy) and 33%(24Gy) per arm. pCR/RCB 0-1 rates were 18%/27% in the entire cohort and 6%/18%(0Gy), 29%/29%(9Gy), and 19%/33%(24Gy), respectively. Conclusion: The addition of 24Gy preop RT to aPD1 significantly increased tumor TCI in HR+/HER2- early-stage BC. Non-irradiated nodal response rates were promising despite over one-third of the study population with grade 1/2 tumors and high disease burden, laying the foundation for a future randomized trial comparing the efficacy of this novel approach against standard of care for node-positive HR+/HER2- BC. Citation Format: G. Gupta, A. Y. Ho, F. Gharibpoor, Y. Abdou, J. D. Anampa, R. C. Blitzblau, B. C. Calhoun, D. L. Casey, S. F. Dent, L. A. Carey, J. R. Bellon, L. E. Warren, J. Lu, T. J. Hieken, A. G. Taghian, A. Bardia, T. Traina, G. Plitas, K. Gallagher, K. Daugherty, A. Thompson, I. Krop, A. Wolff, E. Mittendorf, J. Fox, H. Garber, E. Hwang, A. J. Khan, J. P. Loene, R. Mutter, S. Patil, C. Santa-Maria, B. V. Vincent, J. L. Wright, L. Spring.Primary Results from the HR+/HER2- Cohort of TBCRC-053 (P-RAD): A Randomized Trial of No, Low, or High Dose Preoperative RADiation with Pembrolizumab and Chemotherapy in Node-Positive, HER2-Negative Breast Cancer [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr GS2-05.
Influence of Social Media on Food Choices and Consumption Patterns of Undergraduates in a Nigerian University: A Cross-Sectional Study
Okoruwa, Juliet Obiageli , Ovedje, Tina E., Adeleke, F. N., Oladosu, G., Akinboboye, Praise O., Bolajoko, Opeyemi , Oladosu, Gbenga S. , Bolajoko, Opeyemi

BioSocial Health journal | January 31, 2026 | Volume: 2 | Issue: 3 | Pages: 109-115

10.34172/bshj.83 Get It

Introduction: Social media plays a significant role in shaping the behaviors of undergraduates, including food choices. This study examined the influence of social media on food choices and consumption patterns among undergraduates at a Nigerian university. Methods: A descriptive cross-sectional study of 400 students was conducted using multistage sampling. Data were collected via a pre-tested, interviewer-administered questionnaire on sociodemographic, food consumption, social media use, and its perceived influence on food choices. Analyses were conducted in SPSS v29, reporting means, standard deviations, frequencies, and percentages. Binary logistic regression assessed associations between social media use and food consumption, with significance at P<0.05. Results: Respondents’ mean age was 21.17 ± 2.00 years, with 49.8% aged 15–20. WhatsApp (84.2%) and YouTube (80.7%) were the most used platforms. Over 60% reported that social media influenced their food choices. Confectioneries (70.5%), vegetables (62.5%), and oils (62.3%) were commonly consumed, while alcohol was least consumed (14.5%). Higher social media use was significantly associated with frequent meat and poultry consumption (OR=2.18, P=0.018) and lower odds of oil consumption (OR=0.42, P=0.002). Conclusion: The findings highlight the influence of social media on students’ diets, suggesting the need for nutrition professionals to promote healthier food choices through social platforms.
Recommendations for Advanced Practice Provider Postgraduate Training Programs in the United States: A Work Product of the Advanced Practice Provider Postgraduate Training Task Force of the Society of Critical Care Medicine
Ricker, Melissa, Abide, Aimee, Bakshi, Vishal, Bane, Tina, Bhullar, Simrit K., Byrd, Cindy , Fuller, Todd E., Gunville, Cameron, Hogan, Brett , Nugent, Katherine Lyn, Pandya, Komal , Peacock, Sarah, Pisa, Michael, Meissen, Heather H., McLaughlin, Diane , Boling, Bryan , Farley, Thomas, Newman, Christopher, Nugent, Katherine Lyn, Peacock, Sarah, Meissen, Heather

Critical Care Medicine | January 30, 2026 | Volume: 54 | Issue: 4 | Pages: 825-835

10.1097/ccm.0000000000007061 | PMID 41615242 Get It

OBJECTIVES: The overall goal of this work is to discuss the various topics associated with critical care advanced practice provider (APP) postgraduate training programs and provide resources for new, developing and existing programs. DESIGN: Three rounds of voting until consensus achieved. SETTING: Electronic surveys, followed by virtual meeting. SUBJECTS: Critical care APPs, physicians, a pharmacist, and a nurse were also included to ensure multidisciplinary representation. All subjects resided and practiced in the United States with a history of education scholarship or post-graduate training leadership. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The workgroup included 14 APPs (ten nurse practitioners and four physician associates), three physicians, one pharmacist, and one registered nurse from 14 institutions across the United States. The workgroup identified six areas of concentration: administration, audience, program structure, curriculum, procedural competence, and accreditation. A survey was generated and employed in three rounds. The first two rounds of voting were completed anonymously, the third round was completed as a live meeting until consensus recommendations, defined as 75% agreement or more, were achieved. CONCLUSIONS: Expert consensus was used to generate consensus recommendations for critical care postgraduate training programs based upon 3 rounds of voting.
Surgical Trainee Familiarity and Knowledge of the Commission on Cancer Operative Standards: A National Survey Study
Funk, Elizabeth C, Francescatti, Amanda B. , Pastore, Bell M, Lee, Catherine, Boffa, Daniel J, Dossett, Lesly A, Weigel, Ronald J, Teshome, Mediget , Vreeland, Timothy J. , Dossett, Lesly A. , Baskin, Alison S. , Funk, Elizabeth C., Sample, Jack W. , Pastore, B, Boffa, Daniel J. , Weigel, Ronald J. , Hieken, Tina J. , Wang, Tracy S. , Zaveri, Shruti R

Journal of the American College of Surgeons | January 27, 2026 | Volume: 242 | Issue: 6 | Pages: 1657-1668

10.1097/xcs.0000000000001800 | PMID 41589875 Get It

BACKGROUND: The Commission on Cancer (CoC) implemented 6 operative standards to reduce technical variation in cancer surgery. Although designed to guide surgeons in performing key oncologic techniques, these standards also provide a framework for teaching high-quality cancer surgery to trainees. We assessed surgical trainees’ familiarity with the CoC Operative Standards and the underlying principles of cancer surgery to identify knowledge gaps and opportunities for improved education. STUDY DESIGN: The American College of Surgeons Cancer Surgery Standards Program distributed an anonymous survey to general surgery residents and surgical fellows across the US. Questions addressed the CoC Operative Standards and cancer surgery principles, with scores calculated on the basis of correctness. Univariate logistic regression evaluated associations between trainee or program characteristics and knowledge. Trainees were also asked about their role in procedural documentation, given the synoptic operative report requirements of the standards. RESULTS: A total of 244 surveys were completed by 205 residents and 39 fellows. Fellows reported greater familiarity with the CoC Operative Standards (68% vs 24%, p < 0.001). Only 30% of trainees reported receiving a formal curriculum on the standards. Correct response rates were 30% for CoC Operative Standards questions vs 50% for cancer surgery principles, with minimal association between knowledge and trainee or program characteristics. Most residents (71%) reported contributing to operative documentation. CONCLUSIONS: Surgical trainees demonstrated limited knowledge of the CoC Operative Standards, highlighting the need for multifaceted educational strategies at the national and institutional levels. Incorporating education about the CoC Operative Standards into surgical training can help emphasize the importance of performing and documenting critical elements of cancer operations.
Regulatory T-cell Sensing of Extracellular ATP via P2RX7 Promotes Their Accumulation and Suppression and Drives Lung Tumor Growth
Santiago-Carvalho, Igor , Francisco, Ronaldo da Silva , Macedo, Bruna de Gois , Salgado, Caio Loureiro , Stoll, Carly R. , Shao, Samantha C. , Beniwal, Angad , Kwok, Tina , Banuelos, Alma , Cione, Marcos Pinheiro , White, Emily , Johnston, Tyler, Leff, Chloe , Silva-Junior, Ildefonso , Souza, Fabio Carvalho de, Thant, Win , Fernandez-Bussy, Sebastian, Abia-Trujillo, David, Vu, Linh H, Husta, Bryan C, Copland, John A. , Gounari, Fotini , Justilien, Verline , Cione, Marcos Vinícios Pinheiro , Francisco, Ronaldo , Macedo, Bruna Gois , Johnston, Tyler M , Leff, Chloe Liliana , Carvalho de Souza, Fabio , Pandya, Prita , D'Império Lima, Maria Regina , Fernandez-Bussy, Sebastian , Abia-Trujillo, David , Vu, Linh H , Tran, Nhan L , Husta, Bryan C , Copland, John A , Gounari, Fotini , Justilien, Verline , Lancaster, Jessica N , Borges da Silva, Henrique , Silva, Ildefonso , Pandya, Prita , Lima, Maria Regina D’Império , Tran, Nhan L. , Lancaster, Jessica N. , Silva, Henrique Borges da

Cancer Immunology Research | January 21, 2026 | Volume: 14 | Issue: 4 | Pages: 658-675

10.1158/2326-6066.cir-25-0567 | PMID 41564348 Get It

Abstract Lung cancer is the leading cause of cancer-related deaths worldwide, and despite advances in treatment, immune suppression remains an obstacle to effective therapy. Effector CD4+ T cells (CD4+ Teff) are critical for antitumor immunity, but their function is often inhibited by regulatory T cells (Treg), which accumulate in lung tumors and mediate suppressive functions through multiple mechanisms. This suppression leads to tumor progression and poor patient outcomes. However, the mechanisms underlying Treg-mediated suppression are not fully understood. Herein, we identify the extracellular adenosine 5-triphosphate receptor P2RX7 as a key regulator of Treg function in lung tumors. In a murine lung cancer model induced by Lewis lung carcinoma cells, we found that P2RX7 enhanced the suppressive capacity of tumor-infiltrating Tregs, promoting tumor growth. In T cell–specific P2RX7-knockout (P2RX7-KO) mice, reduced Treg infiltration was accompanied by increased CD4+ Teff accumulation and improved tumor control. Treg-specific P2RX7-KO mice exhibited reduced tumor growth, confirming a Treg-intrinsic role of P2RX7. Suppression assays revealed that tumor-infiltrating wild-type Tregs had greater suppressive activity compared with P2RX7-KO Tregs, which failed to inhibit type 1 and follicular helper T–like responses. This was associated with increased tumor-specific IgG production by lung B cells in P2RX7-KO mice. We also observed that wild-type Tregs expressed higher levels of the immunosuppressive molecule CTLA-4 when compared with P2RX7-KO Tregs. Thus, we conclude that P2RX7 expression on Tregs is essential for their suppressive function in lung cancer and targeting P2RX7 may constitute a strategy to improve lung cancer treatment by alleviating Treg-mediated immune suppression.
National Cancer Statistics: American College of Surgeons Cancer Programs Annual Report from 2022 Participant User File
Habermann, Elizabeth B, Day, Courtney N. , Palis, Bryan E., Boffa, Daniel, Alanee, Shaheen , Habermann, Elizabeth B. , Boffa, Daniel J. , Hieken, Tina J. , Weigel, Ronald J. , Boughey, Judy C.

Journal of the American College of Surgeons | January 21, 2026 | Volume: 242 | Issue: 6 | Pages: 1614-1630

10.1097/xcs.0000000000001747 | PMID 41562441 Get It

Biomarker analysis of circulating tumor DNA in clinical stage III melanoma patients treated with neoadjuvant immunotherapy combined with targeted therapy
Yalon, Mariana , Bogan, Aaron, Block, Matthew S. , Hieken, Tina J. , Bogan, Aaron , Stoff, Ronen , Bogan, Aaron W , Hieken, Tina J , Routman, David M.

Therapeutic Advances in Medical Oncology | January 20, 2026 | Volume: 18 | Issue: No issue available | Pages: No page available

10.1177/17588359251412729 | PMID 41567809 Get It

Background: Circulating tumor DNA (ctDNA) is predictive of recurrence in resected stage III melanoma, yet its role in the neoadjuvant setting for clinical stage III (cSIII) is unclear. Objective: Assess the association between ctDNA and outcomes following neoadjuvant immunotherapy (IO) + targeted therapy (TT) in cSIII melanoma. Design: Patients in the NeoACTIVATE study were treated with neoadjuvant IO + TT, underwent lymphadenectomy, and received adjuvant immunotherapy. Methods: Patients with ctDNA testing performed at baseline, pre- and post-operation were analyzed. Baseline positron emission tomography–computed tomography volumetrics and surgical, major pathological responses (MPR) were assessed. Results: Thirteen patients had serial ctDNA, 10 (77%) were detectable at baseline, and 9/10 (90%) had ctDNA clearance. Seven (54%) achieved MPR, all with undetectable preoperative ctDNA, yet 3/7 (43%) had disease recurrence. Conclusion: ctDNA and MPR are poor predictors of recurrence following neoadjuvant IO + TT for cSIII melanoma patients. Further studies are warranted to define the role of ctDNA in this setting.
NCCN Guidelines® Insights: Small Cell Lung Cancer, Version 2.2026
Ganti, Apar Kishor P., Loo, B., Bassetti, Michael, Chiang, Anne, D’Avella, Christopher , Daly, Megan, Dowlati, Afshin, Edelman, Martin, Florsheim, Charles, Grecula, J.C., Hann, Christine, Khalil, Maya, Lee, R., Merritt, Robert E. , Mohindra, Nisha , Molina, Julian R. , Moran, C Solis, Mulvey, Claire K. , Osmundson, Evan C., Patel, S. B., Patil, Tejas, Puri, S., Qin, Angel, Tailor, Tina D. , Waqar, Saiama N., Cassara, Carly J., Ramakrishnan, Swathi , Ganti, Apar Kishor , Loo, Billy W. , Badiyan, Shahed N. , Bassetti, Michael, Bestvina, Christine M. , Chiang, Anne, Choudhury, Noura J. , Daly, Megan, Gold, Kathryn Ann , Goldman, Jonathan W. , Hann, Christine L. , Lee, Robert P. , Malhotra, Jyoti Dhar , Pokharel, Saraswati , Qin, Angel , Sands, Jacob , Shields, Misty Dawn , Waqar, Saiama N

Journal of the National Comprehensive Cancer Network | January 8, 2026 | Volume: 24 | Issue: 1 | Pages: No page available

10.6004/jnccn.2026.0002 | PMID 41671459 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer provide recommendations for diagnostic workup, staging, and treatment. These NCCN Guidelines Insights highlight recent updates, with a particular focus on changes to systemic therapies and radiation treatment in the NCCN Guidelines for Small Cell Lung Cancer.
Comparing Transverse Sinus Stenosis in Lateral Skull Base Cerebrospinal Fluid Leaks to Idiopathic Intracranial Hypertension
Wilson, Penny , Doucette, Madison M., Rao, Dinesh , Fermo, Olga , Hodge, David O., Roeber, Tina S., Breen, Joseph T. , Raymond, Mallory , Wilson, Prishae , Valencia, Bastien A. , Murray, John V, Fermo, Olga P, Murray, John Vincent , Hodge, David O. , Raymond, Mallory J

Otology & Neurotology | December 24, 2025 | Volume: 47 | Issue: 3 | Pages: e593-e599

10.1097/mao.0000000000004816 | PMID 41439786 Get It

Objective: To compare the prevalence and patterns of transverse sinus stenosis (TSS) in patients with lateral skull base spontaneous cerebrospinal fluid (sCSF) leaks and idiopathic intracranial hypertension (IIH), to clarify its role in leak pathogenesis and implications for venous-directed therapies. Study design: Retrospective case-control study. Setting: Single tertiary care institution. Patients: Adults with lateral skull base sCSF leaks confirmed by clinical, laboratory, or surgical findings, and adults with IIH without cranial CSF leaks meeting Modified Dandy criteria. Intervention: Independent magnetic resonance venography evaluation by 2 fellowship-trained neuroradiologists. Main outcome measures: Presence, laterality, and severity of TSS. Results: Eighteen patients with sCSF leaks and 78 patients with IIH were included. The rate of individual TSS, including both unilateral and bilateral cases, was higher in the IIH cohort than in the sCSF leak cohort (bilateral TSS: n=66, 84.6% vs. n=6, 33.3%; P <0.001). Severe bilateral TSS was observed more in the IIH cohort (n=40, 51.3%) compared with the sCSF leak cohort (n=1, 5.6%; P <0.001). Conclusions: Though patients with lateral skull base sCSF leaks have TSS, the significantly lower rate compared with patients with IIH suggests that TSS may play a lesser role in the pathogenesis of lateral skull base defects. These findings indicate that the role of transverse sinus stenting in lateral skull base sCSF leaks remains uncertain and highlight the need to further investigate local remodeling processes when considering the role of venous sinus stenting in this population.